


Data Sheet

| | |
|--------------------|---|
| Product Name: | DMA |
| Cat. No.: | CS-1309 |
| CAS No.: | 188860-26-6 |
| Molecular Formula: | C ₂₇ H ₂₈ N ₆ O ₂ |
| Molecular Weight: | 468.55 |
| Target: | Others |
| Pathway: | Others |
| Solubility: | DMSO : ≥ 54 mg/mL (115.25 mM) |



BIOLOGICAL ACTIVITY:

DMA is a fluorescent compound (λ_{ex} =340 nm, λ_{em} =478 nm). IC₅₀ & Target: IC₅₀: 3.4 μ M (HeLa cell), 5.3 μ M (MCF7 cell)^[1] **In Vitro:** The newly synthesized bisbenzimidazole derivatives DMA (6c) is evaluated for their cytotoxicity against human tumor cell lines, which are cervix carcinoma cell line (HeLa), breast carcinoma cell line (MCF7) and brain glioma cell line (U87) in comparison to Hoechst. In case of MCF7, the IC₅₀ is observed at 5.3 μ M for DMA. The IC₅₀ determined in the case of HeLa is 3.4 μ M for DMA^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: Various human tumor cells (U87, HeLa and MCF7) are maintained as monolayer at 37°C in 5% CO₂ using DMEM medium. Approximately 3000-8000 cells/well are seeded in 96-well plates containing 200 μ L of medium and incubated for 24 h. The culture medium is replaced by fresh medium containing 1, 10, 50, 100 μ M of DMA (6c) and incubated for 24, 48 and 72 h. The cell viability is determined by the MTT assay. The light absorbance is measured using a microplate reader^[1].

References:

[1]. Singh M, et al. Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur J Med Chem. 2011 Feb;46(2):659-69.

CAIndexNames:

2,5'-Bi-1H-benzimidazole, 2'-(3,4-dimethoxyphenyl)-5-(4-methyl-1-piperazinyl)-

SMILES:

CN1CCN(C2=CC=C3C(N=C(C4=CC=C5C(N=C(C6=CC=C(OC)C(OC)=C6)N5)=C4)N3)=C2)CC1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA